American Society of Hematology Annual Meeting

How Monjuvi Plus Revlimid, Rituxan Work to Treat Follicular Lymphoma

December 26th 2024, 2:00pm

Video

The treatment combination was found to reduce the risk of follicular lymphoma progression or death by 57%, a study has shown.

Monjuvi Combination May Improve Survival in Follicular Lymphoma

December 25th 2024, 7:00pm

Article

Monjuvi plus Revlimid and Rituxan demonstrated improved progression-free survival for patients with relapsed or refractory follicular lymphoma.

Top 4 Stories From the 2024 ASH Annual Meeting

December 24th 2024, 4:00pm

Article

CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple myeloma and other blood cancers.

Real-World Data May Confirm Monjuvi’s Efficacy in Large B-Cell Lymphoma

December 24th 2024, 2:00pm

Article

The real-world effectiveness of Monjuvi for relapsed or refractory diffuse large B-cell lymphoma in the U.S. was demonstrated, according to data from a retrospective analysis.

Epkinly Leads to Responses in Heavily Pretreated Patients With CLL

December 23rd 2024, 2:00pm

Article

Among patients with heavily pretreated chronic lymphocytic leukemia, treatment with Epkinly monotherapy showed deep responses.

Darzalex Regimen May Improve MRD Responses in Multiple Myeloma

December 21st 2024, 3:00pm

Article

Patients newly diagnosed with multiple myeloma who are transplant ineligible or deferred may benefit from receiving a Darzalex treatment combination.

What is Follicular Lymphoma and Why Are Better Treatments Needed?

December 19th 2024, 2:00pm

Video

CURE® spoke with an expert about follicular lymphoma, a disease that is still considered incurable.

Imbruvica-Venetoclax Shows Promise in Managing CLL

December 18th 2024, 2:00pm

Article

A combination of Imbruvica and venetoclax showed significantly prolonged progression-free survival in patients with untreated CLL, an expert explained.

Black Patients With Myeloma Face Taste, Skin Side Effects from Talvey

December 17th 2024, 4:00pm

Article

Black patients may be more affected by certain side effects from Talvey compared with White patients with multiple myeloma, an expert told CURE®.

Tecartus After Outpatient Lymphodepletion Safe, Effective in B-ALL and MCL

December 16th 2024, 4:00pm

Article

Outpatient lymphodepletion followed by Tecartus was found to be safe and effective in treating B-cell acute lymphoblastic leukemia and mantle cell lymphoma.